Seven criteria, each scored 0 to 100 on a published scale, weighted into one number.
Below average. Thermo Fisher Scientific scores higher than 33% of the 1,794 companies Ryufin scores.
Carried by capital allocation and cycle position, held back by valuation and return on new capital.
Healthcare median 27 · all companies 50
26% of the score
Thermo Fisher Scientific is valued at 23.9x its operating profit before acquisition amortisation (EBITA), including debt: a rich multiple.
18% of the score
Over 7 years the business earned 9.8% a year after tax on the capital it uses.
16% of the score
Over 6 years yearly profit fell by 2 cents for every dollar earned. New capital earned -4.8%, and 52% of profit went back into the business.
14% of the score
How management spends the money: shares bought back or issued, and whether assets grow faster than the business they serve.
12% of the score
Today's operating margin of 18% is 1.00x its normal 18%: close to its usual level. Normal is half the 10 year median, half the last four years, so a margin that has held is not taken for a peak.
8% of the score
What the debt weighs against the profit that has to carry it.
6% of the score
Whether the reported profit arrives as cash, and whether the accounts show the usual signs of stretching.
Each criterion earns 0 to 100 points on the scale drawn under it, and the RyuScore is their average weighted 26, 18, 16, 14, 12, 8 and 6. Scales bend in the company's favour between their ends, so an ordinary figure is never already near zero. Where a criterion cannot be measured from the filings it is taken out and the remaining weights scale up; a company needs 60% of the weight covered, and always a price, to get a score.
Built from the company's annual and quarterly filings with the SEC and today's share price. Banks, insurers and property trusts are not scored: their debt is their raw material, so these yardsticks mean something else there. Figures as of 2026-06-27, latest annual report FY2025.
The closest names by size in the same industry